198 related articles for article (PubMed ID: 11158747)
1. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
Polk RE; Brophy DF; Israel DS; Patron R; Sadler BM; Chittick GE; Symonds WT; Lou Y; Kristoff D; Stein DS
Antimicrob Agents Chemother; 2001 Feb; 45(2):502-8. PubMed ID: 11158747
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.
Polk RE; Crouch MA; Israel DS; Pastor A; Sadler BM; Chittick GE; Symonds WT; Gouldin W; Lou Y
Pharmacotherapy; 1999 Dec; 19(12):1378-84. PubMed ID: 10600086
[TBL] [Abstract][Full Text] [Related]
4. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
[TBL] [Abstract][Full Text] [Related]
5. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Tran JQ; Petersen C; Garrett M; Hee B; Kerr BM
Clin Pharmacol Ther; 2002 Dec; 72(6):615-26. PubMed ID: 12496743
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
9. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Hendrix CW; Wakeford J; Wire MB; Lou Y; Bigelow GE; Martinez E; Christopher J; Fuchs EJ; Snidow JW
Pharmacotherapy; 2004 Sep; 24(9):1110-21. PubMed ID: 15460171
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M
Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026
[TBL] [Abstract][Full Text] [Related]
20. Indinavir and rifabutin drug interactions in healthy volunteers.
Kraft WK; McCrea JB; Winchell GA; Carides A; Lowry R; Woolf EJ; Kusma SE; Deutsch PJ; Greenberg HE; Waldman SA
J Clin Pharmacol; 2004 Mar; 44(3):305-13. PubMed ID: 14973305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
